secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENvue Medical, Inc. (FEED)
CIK:        0001326706
Form:       8-K
Filed at:   2024-03-28T23:59:59+00:00
Accession:  0001493152-24-011629
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NanoVibronix signs $1.1M R&D deal with Veranex for next-gen UroShield, PainShield
--------------------------------------------------------------------------------

- Entered into agreement with Veranex for R&D services for next-gen UroShield and PainShield; term ~50 weeks; fee up to ~$1.1M.
- Fee payable monthly, due 45 days after invoice; late fee 1.5% per month; Veranex may suspend services if payment not made.
- Either party may terminate on 60 days' notice; Veranex can also terminate for repeated late payments or relationship issues.
- CEO Brian Murphy stated partnership aims to add therapeutic functionality and reduce cost of goods; press release dated March 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/0001493152-24-011629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326706/000149315224011629/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer